Pharma BD Deal Intelligence

Blackstone Group Inc. / Alnylam Pharmaceuticals Inc.

2020 · Co-Development · $2.0B · Complete

Announcement Sentiment

Strongly positive

Blackstone and Alnylam entered a $2B strategic financing collaboration. Blackstone Life Sciences purchased 50% of Alnylam's inclisiran royalties and commercial milestones for $1B and committed up to $150M for vutrisiran and ALN-AGT R&D, plus $100M equity. GSO Capital Partners provided up to $750M senior secured term loan. One of the largest private biotech financings ever.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Apr 13, 2020
Closed Apr 13, 2020
Deal value $2.0B
Deal type Co-Development
Therapeutic area Hypercholesterolemia (inclisiran); cardiometabolic disease (vutrisiran, ALN-AGT)
Indications Hypercholesterolemia (inclisiran); cardiometabolic disease (vutrisiran, ALN-AGT)
Key assets Inclisiran (PCSK9 siRNA); vutrisiran; ALN-AGT
Mechanism RNA interference (siRNA)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals